<DOC>
	<DOCNO>NCT01742585</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled multi-center study examine efficacy safety ASP1585 chronic kidney disease patient hyperphosphatemia dialysis .</brief_summary>
	<brief_title>A Phase 3 Study ASP1585 Chronic Kidney Disease Patients With Hyperphosphatemia Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Chronic kidney disease patient ( eGFR &lt; 60 mL/min/1.73 m2 ) Serum phosphorus measurement â‰§4.6 mg/dl , &lt; 9.0 mg/dl Written inform consent Patients gastrointestinal surgery enterectomy Patients severe cardiac disease Patients severe constipation diarrhea Patients history complication malignant tumor Patients uncontrolled hypertension Patients treat parathyroid intervention within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Not dialysis</keyword>
	<keyword>ASP1585</keyword>
	<keyword>Bixalomer</keyword>
</DOC>